{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-113551","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.121442+00:00","generated_at":"2026-06-22T16:45:09.489455+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Novavax appoints Richard J. Rodgers to board as independent director","bullets":["Board size increased from 7 to 8; Rodgers appointed effective Oct 29, 2022 as Class I director until 2023 annual meeting.","Rodgers has biopharma leadership background as co-founder/CFO of TESARO (acquired by GSK for >$5B) and CFO of Abraxis.","Initial equity grant: options for 17,095 shares and 11,400 RSUs under 2015 Stock Incentive Plan.","No committee assignments yet; affirmed independent with no material related-party transactions.","Indemnification agreement entered into; press release issued Nov 1, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-113551","json":"https://secwatch.observer/filing/0001104659-22-113551.json","markdown":"https://secwatch.observer/filing/0001104659-22-113551.md","text":"https://secwatch.observer/filing/0001104659-22-113551.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000110465922113551/0001104659-22-113551-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000110465922113551/tm2229431d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T16:45:09.489455+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"294f79092f","claim":"Richard J. Rodgers was appointed as Director at NOVAVAX INC.","evidence_excerpt":"On October 29, 2022, the Board of Directors (the “Board”) of Novavax, Inc. (the “Company”) voted to increase the size of the Board from seven members to eight members and to appoint Richard J. Rodgers to the Board to fill the resulting vacancy, effective as of October 29, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465922113551/0001104659-22-113551-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}